U.S. Markets closed

Strength Seen in Conatus Pharmaceuticals (CNAT): Stock Soars 56.7%

Zacks Equity Research

Conatus Pharmaceuticals Inc. (CNAT) was a big mover last session, as the company saw its shares rise nearly 57% on the day. The move came on solid volume with more than 6 million shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.34 to $6.24 in the past one-month time frame.

The company has seen two positive estimate revisions in the past 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Conatus Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked medical stocks worth considering include Cardica Inc. (CRDC), ICU Medical, Inc. (ICUI) and NeuroMetrix Inc. (NURO). All these stocks have a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


CARDICA INC (CRDC): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

NEUROMETRIX INC (NURO): Free Stock Analysis Report

Zacks Investment Research